Insmed jumps as new drug launch momentum drives bullish 2026 revenue outlook

Insmed Incorporated (INSM) is up 6.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The move higher appears tied to the company’s fourth-quarter and full-year 2025 results and, more importantly, upbeat 2026 revenue expectations for its newer product BRINSUPRI following a strong early commercial launch. Investors also seemed to focus on continued momentum in ARIKAYCE and pipeline/regulatory updates that reinforce a growth narrative despite ongoing losses.

Details:

Sources:

Insmed Investor Relations, Fierce Pharma

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 111 times in the past 6 months. Of those trades, 0 have been purchases and 111 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

• MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 35 sales selling 267,135 shares for an estimated $41,532,420.
• ORLOV S NICOLE SCHAEFFER (Chief People Strategy Officer) has made 0 purchases and 8 sales selling 106,520 shares for an estimated $16,949,988.
• LEO LEE has made 0 purchases and 5 sales selling 75,000 shares for an estimated $14,692,249.
• WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 33 sales selling 77,393 shares for an estimated $13,068,271.
• MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 18 sales selling 55,200 shares for an estimated $9,127,795.
• MELVIN MD SHAROKY has made 0 purchases and 2 sales selling 30,000 shares for an estimated $5,554,100.
• ELIZABETH M ANDERSON has made 0 purchases and 2 sales selling 15,000 shares for an estimated $2,981,600.
• SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 5,390 shares for an estimated $925,675.
• ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 4 sales selling 5,081 shares for an estimated $870,241.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$INSM Hedge Fund Activity

We have seen 407 institutional investors add shares of $INSM stock to their portfolio, and 320 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• PRICE T ROWE ASSOCIATES INC /MD/ removed 2,892,000 shares (-41.7%) from their portfolio in Q4 2025, for an estimated $503,323,680
• BLACKROCK, INC. added 2,700,148 shares (+21.8%) to their portfolio in Q4 2025, for an estimated $469,933,757
• CAPITAL INTERNATIONAL INVESTORS removed 2,402,182 shares (-31.8%) from their portfolio in Q4 2025, for an estimated $418,075,755
• RTW INVESTMENTS, LP added 1,758,321 shares (+57.0%) to their portfolio in Q4 2025, for an estimated $306,018,186
• DEEP TRACK CAPITAL, LP removed 1,750,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $252,017,499
• ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,606,949 shares (-56.2%) from their portfolio in Q3 2025, for an estimated $231,416,725
• QUBE RESEARCH & TECHNOLOGIES LTD removed 1,544,315 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $268,772,582

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$INSM Congressional Stock Trading

Members of Congress have traded $INSM stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $INSM stock by members of Congress over the last 6 months:

• REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 10/03, 09/22.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• UBS issued a "Buy" rating on 01/06/2026
• TD Cowen issued a "Buy" rating on 12/18/2025
• Goldman Sachs issued a "Buy" rating on 12/18/2025
• HC Wainwright & Co. issued a "Buy" rating on 12/18/2025
• Wells Fargo issued a "Overweight" rating on 12/16/2025
• Mizuho issued a "Outperform" rating on 12/01/2025
• RBC Capital issued a "Outperform" rating on 10/31/2025

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 15 analysts offer price targets for $INSM in the last 6 months, with a median target of $223.0.

Here are some recent targets:

• Matthew Harrison from Morgan Stanley set a target price of $162.0 on 01/30/2026
• Eliana Merle from Barclays set a target price of $231.0 on 01/28/2026
• Adam Walsh from Roth Capital set a target price of $212.0 on 01/23/2026
• Leonid Timashev from RBC Capital set a target price of $200.0 on 01/21/2026
• Ashwani Verma from UBS set a target price of $215.0 on 01/06/2026
• Andrea Tan from Goldman Sachs set a target price of $225.0 on 12/18/2025
• Vamil Divan from Guggenheim set a target price of $221.0 on 12/18/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.